TiGenix tightens allogeneic focus

Following a positive opinion in Europe for its cell therapy for fistulas in Crohn’s disease, TiGenix NV has tightened its therapeutic focus to concentrate on allogeneic therapies and in particular, on inflammatory conditions associated with immune-mediated diseases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.